Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and DA-EPOCH-R in MYC-Associated B-Cell Lymphomas
NCT02213913Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jul 2014
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in B cell lymphoma and double hit lymphoma (DHL), sponsored by University of Chicago. Primary endpoints: Dose-limiting Toxicity at 21 days and Progression-free Survival at 5 years. Started Jul 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
B cell lymphomadouble hit lymphoma (DHL)
Beyond the preview
Go deeper on NCT02213913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213913.